PFKFB3 Mediates Tubular Cell Death in Cisplatin Nephrotoxicity by Activating CDK4

Lu Wen,Qingqing Wei,Man J. Livingston,Guie Dong,Siyao Li,Xiaoru Hu,Ying Li,Yuqing Huo,Zheng Dong
DOI: https://doi.org/10.1016/j.trsl.2022.10.001
IF: 10.171
2023-01-01
Translational Research
Abstract:Nephrotoxicity is a major side effect of cisplatin, a widely used cancer therapy drug. However, the mecha-nism of cisplatin nephrotoxicity remains unclear and no effective kidney protective strategies are available. Here, we report the induction of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in both in vitro cell culture and in vivo mouse models of cisplatin nephrotoxicity. Notably, PFKFB3 was mainly induced in the nucleus of kidney tubular cells, suggesting a novel function other than its canonical role in glycolysis. Both pharmacological inhibition and genetic silencing of PFKFB3 led to the suppression of cis-platin-induced apoptosis in cultured renal proximal tubular cells (RPTCs). Moreover, cisplatin-induced kid-ney injury or nephrotoxicity was ameliorated in renal proximal tubule-specific PFKFB3 knockout mice. Mechanistically, we demonstrated the interaction of PFKFB3 with cyclin-dependent kinase 4 (CDK4) during cisplatin treatment, resulting in CDK4 activation and consequent phosphorylation and inactivation of reti-noblastoma tumor suppressor (Rb). Inhibition of CDK4 reduced cisplatin-induced apoptosis in RPTCs and kidney injury in mice. Collectively, this study unveils a novel pathological role of PFKFB3 in cisplatin neph-rotoxicity through the activation of the CDK4/Rb pathway, suggesting a new kidney protective strategy for cancer patients by blocking PFKFB3.
What problem does this paper attempt to address?